Île Saint-Louis, eleven hectares in size, is one of two natural islands in the Seine river, in Paris, France. Île Saint-Louis is connected to the rest of Paris by four bridges to both banks of the river and to the Île de la Cité by the Pont Saint-Louis.

During the past decade, Paris - Saint Louis conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Paris - Saint Louis" #1 sponsor was "Intergroupe Francophone de Cancerologie Thoracique" with 8 trials, followed by "French Innovative Leukemia Organisation" with 3 trials sponsored, "ETOP IBCSG Partners Foundation" with 1 trials sponsored, "Nantes University Hospital" with 1 trials sponsored and "Societe Française de Medecine d'urgence" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Paris - Saint Louis" #1 collaborator was "Acute Leukemia French Association" with 2 trials as a collaborator, "French Intergroup of Myeloproliferative syndromes" with 2 trials as a collaborator, "Groupe Francais De Pneumo-Cancerologie" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Frontier Science Foundation, Hellas" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Paris - Saint Louis" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "ALK Gene Mutation" (1 trials), "ALK Gene Rearrangement Positive" (1 trials), "AML" (1 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "Paris - Saint Louis" in a lesser frequency.

Most popular intervention types in "Paris - Saint Louis" are "Drug" (10 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (2 trials), "Pemetrexed" (2 trials), "Add-on therapy" (1 trials), "Bevacizumab" (1 trials) and "CPX-351" (1 trials). Other intervention names were less common.

The vast majority of trials in "Paris - Saint Louis" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Paris - Saint Louis". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Paris - Saint Louis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Paris - Saint Louis, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".